Celltrion, Hospira, J&J, Nippon Kayaku autoimmune, biosimilars news
Celltrion filed suit in the U.S. District Court for the District of Massachusetts seeking a declaratory judgment that three patents from Johnson & Johnson covering the pharma's autoimmune drug Remicade infliximab are invalid and unenforceable. In Celltrion Healthcare Co., Ltd. et al vs. Janssen Biotech, Inc., Celltrion is seeking a judgment that J&J's U.S. Patent Nos. 5,919,452, 6,284,471 and 7,223,396 covering Remicade are invalid and unenforceable.
This half, Celltrion plans to submit a BLA to FDA for Remsima infliximab - a biosimilar of Remicade - to treat rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and psoriasis. According to J&J, its patents covering Remicade expire in 2018. The pharma reported 2013 U.S. sales of the drug, which is partnered with Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.), of $3.9 billion. ...